Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

Homecompany99% Bulk Ribociclib Lee011 Rebosini Powder CAS 1256963-02-6
LEE011/ Ribociclib
LEE011/ Ribociclib
LEE011/ Ribociclib

99% Bulk Ribociclib Lee011 Rebosini Powder CAS 1256963-02-6

Price USD10.00USD15.00USD20.00
Packge 1kg1kg1kg
  • Min. Order:1kg
  • Supply Ability:20tons
  • Time:2022-07-07

Product Details

  • Product NameLEE011/ Ribociclib
  • CAS No.1256963-02-6
  • MFC22H29ClN8
  • MW440.97
  • AppearanceSolidBeige
  • Boiling point 679.3±65.0 °C(Predicted)
  • density 1.31±0.1 g/cm3(Predicted)
  • Melting point >180°C (dec.)
  • storage temp. -20°C Freezer

Basic Info.

Model NO.
linwo
Payment
Bitcoin/Wu/Mg/Wire Transfer
Minimum
10g
Delivery Time
1-3 Days
Shipping
Worldwide
Transport Package
Safe and Fast Delivery
Specification
10g, 100g, 1kg
Trademark
linwo
Origin
China
HS Code
2937290090
Production Capacity
20000kg Per Month

Product Description

99% Bulk Ribociclib LEE011 Rebosini Powder CAS 1256963-02-6

Product Name: LEE011
Synonyms: Rebosini;LEE011;CDK4/6 inhibitor;CDK4 inhibitor;CDK4-IN-1;CS-842;4-(5-Chloro-3-isopropyl-1H-pyrazol-4-yl)-N-(5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)pyrimidin-2-amine;CDK 4/6 Inhibitor, >=98%
CAS: 1256963-02-6
MF: C22H29ClN8
MW: 440.97
Appearance: White Powder
Shipping: Safety and fast, guarantee delivery

LEE011 (also known as ribociclib) is a CDK4/6 inhibitor. It has been recently approved by FDA (brand name: Kisqali®) to be combined with an aromatase inhibitor for initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer. It inhibits the growth of tumor cells by arresting the cells at the G1 checkpoint, which prevents the tumor cells from proliferating. In the phase III trial, it demonstrating statistically significant improvement in progression-free survival (PFS) compared to letrozole alone at the first pre-planned interim analysis. 


Company Profile Introduction

New material technology research and development、Technology popularization、 Technical consulting、Technology transfer、Medical technology r&d

Recommended supplier

  • Since:2022-03-18
  • Address: Room 601, Unit 1, Building 1, 188 Xinhuali, North Xinhua Road, Xiangdu District, Xingtai city, Hebei
INQUIRY